AI enabled biosensing QBI combines synthetic biology, novel cell measurement technologies, and AI/machine learning to engineer customized, multiplexed biosensors and assays. Sales opportunities exist in pharmaceutical process control and diagnostics where AI-driven sensor optimization can reduce time-to-result and improve assay performance.

sdAb library Recent launch of a high-diversity synthetic sdAb library with AI-enabled screening presents a pathway to accelerate antibody discovery for customers needing rapid development of diagnostics or targeted therapeutics.

industrial collaboration Historical partnerships in biogas and biofuel projects indicate a capability and interest in industrial bioprocess monitoring and renewable energy applications. Potential upsell to customers in agri-biotech, waste-to-value, and bioprocessing sectors seeking sensors and analytics.

global growth signals Revenue in the low-to-mid single digits with modest funding suggests a nimble, growth-oriented company open to strategic partnerships, co-development, or pilot programs with larger biotech firms seeking scalable sensor platforms and custom assays.

targeted enterprise fit Operating with a small team and leveraging existing tech stack (Cloud/AI, web presence, rapid screening) positions QBI as a fit for services outsourcing, joint ventures, or channel partnerships with larger contract research organizations and biosensor developers.